 SAN DIEGO, March 15, 2021 GLOBE NEWSWIRE -- Adamis Pharmaceuticals Corporation Nasdaq: ADMP Company announced today that in studies conducted at Galveston National Laboratory GNL, University of Texas Medical Branch UTMB at Galveston, hamsters challenged with the virus that causes COVID-19 SARS-CoV-2, resulted in decreased inflammation in the lungs of animals treated with Tempol compared to controls. This is the first data demonstrating that Tempol, a novel antioxidant, can reduce inflammation in animals given the virus SARS-CoV-2 that causes COVID-19. The group plans on submitting the publication to a peer review journal. 